208 related articles for article (PubMed ID: 38002786)
1. Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection.
Zhang Q; Bignotti A; Yada N; Ye Z; Liu S; Han Z; Zheng XL
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002786
[TBL] [Abstract][Full Text] [Related]
2. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
[TBL] [Abstract][Full Text] [Related]
3. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
[TBL] [Abstract][Full Text] [Related]
4. Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19.
Zhang Q; Ye Z; McGowan P; Jurief C; Ly A; Bignotti A; Yada N; Zheng XL
Res Pract Thromb Haemost; 2023 Jan; 7(1):100010. PubMed ID: 36531671
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
[TBL] [Abstract][Full Text] [Related]
6. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
[TBL] [Abstract][Full Text] [Related]
7. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
Marco A; Marco P
J Thromb Thrombolysis; 2021 Aug; 52(2):497-503. PubMed ID: 33866481
[TBL] [Abstract][Full Text] [Related]
8. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.
Joly BS; Darmon M; Dekimpe C; Dupont T; Dumas G; Yvin E; Beranger N; Vanhoorelbeke K; Azoulay E; Veyradier A
J Thromb Haemost; 2021 Sep; 19(9):2193-2198. PubMed ID: 34219357
[TBL] [Abstract][Full Text] [Related]
9. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
[TBL] [Abstract][Full Text] [Related]
10. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
[TBL] [Abstract][Full Text] [Related]
11. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
Turecek PL; Peck RC; Rangarajan S; Reilly-Stitt C; Laffan MA; Kazmi R; James I; Dushianthan A; Schrenk G; Gritsch H; Ewenstein BM; Mellgard B; Erdlenbruch W; Jain N; Binder NB; Mumford AD
Thromb Res; 2021 May; 201():100-112. PubMed ID: 33662796
[TBL] [Abstract][Full Text] [Related]
12. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Matsukawa M; Kaikita K; Soejima K; Fuchigami S; Nakamura Y; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Shimomura H; Sugiyama S; Fujimoto K; Yoshimura M; Nakagaki T; Ogawa H
Am J Cardiol; 2007 Sep; 100(5):758-63. PubMed ID: 17719316
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.
Miura M; Kaikita K; Matsukawa M; Soejima K; Fuchigami S; Miyazaki Y; Ono T; Uemura T; Tsujita K; Hokimoto S; Sumida H; Sugiyama S; Matsui K; Yamabe H; Ogawa H
Thromb Haemost; 2010 Mar; 103(3):623-9. PubMed ID: 20135067
[TBL] [Abstract][Full Text] [Related]
14. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality.
Philippe A; Chocron R; Gendron N; Bory O; Beauvais A; Peron N; Khider L; Guerin CL; Goudot G; Levasseur F; Peronino C; Duchemin J; Brichet J; Sourdeau E; Desvard F; Bertil S; Pene F; Cheurfa C; Szwebel TA; Planquette B; Rivet N; Jourdi G; Hauw-Berlemont C; Hermann B; Gaussem P; Mirault T; Terrier B; Sanchez O; Diehl JL; Fontenay M; Smadja DM
Angiogenesis; 2021 Aug; 24(3):505-517. PubMed ID: 33449299
[TBL] [Abstract][Full Text] [Related]
15. Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients.
Singh K; Kwong AC; Madarati H; Kunasekaran S; Sparring T; Fox-Robichaud AE; Liaw PC; Kretz CA
PLoS One; 2021; 16(2):e0247017. PubMed ID: 33606732
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
Ward SE; Fogarty H; Karampini E; Lavin M; Schneppenheim S; Dittmer R; Morrin H; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Mallon PW; Curley GF; Baker RI; Budde U; O'Sullivan JM; O'Donnell JS;
J Thromb Haemost; 2021 Aug; 19(8):1914-1921. PubMed ID: 34053187
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients.
Thangaraju K; Katneni U; Akpan IJ; Tanaka K; Thomas T; Setua S; Reisz JA; Cendali F; Gamboni F; Nemkov T; Kahn S; Wei AZ; Valk JE; Hudson KE; Roh DJ; Moriconi C; Zimring JC; D'Alessandro A; Spitalnik SL; Francis RO; Buehler PW
Front Med (Lausanne); 2021; 8():817305. PubMed ID: 35087853
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
Doevelaar AAN; Bachmann M; Hölzer B; Seibert FS; Rohn BJ; Bauer F; Witzke O; Dittmer U; Bachmann M; Yilmaz S; Dittmer R; Schneppenheim S; Babel N; Budde U; Westhoff TH
Crit Care Med; 2021 May; 49(5):e512-e520. PubMed ID: 33591004
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.
Rutten B; Maseri A; Cianflone D; Laricchia A; Cristell NA; Durante A; Spartera M; Ancona F; Limite L; Hu D; Li H; Uren NG; de Groot PG; Mannucci PM; Roest M
Eur Heart J Acute Cardiovasc Care; 2015 Feb; 4(1):64-74. PubMed ID: 24833640
[TBL] [Abstract][Full Text] [Related]
20. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
